| Id |
Subject |
Object |
Predicate |
Lexical cue |
| T114 |
0-4 |
Sentence |
denotes |
3.2. |
| T115 |
6-38 |
Sentence |
denotes |
Limitations and more of the same |
| T116 |
39-173 |
Sentence |
denotes |
A large number of drugs approved by the FDA in the past 10 years are new formulations of existing drugs referred to as ‘me too drugs’. |
| T117 |
174-363 |
Sentence |
denotes |
While in some cases these drugs have offered some improvements over older versions, in many cases improvements remain marginal with slight changes in side effects or activity profiles [34]. |
| T118 |
364-511 |
Sentence |
denotes |
Since these drugs have identical mechanism of action to older versions their innovative value and overall benefit is oftentimes insignificant [35]. |
| T119 |
512-624 |
Sentence |
denotes |
Additionally, the molecular effects of several marketed drugs remain unknown despite their proven effectiveness. |
| T120 |
625-765 |
Sentence |
denotes |
For example, acetaminophen is used by millions to treat mild to moderate pain while lithium is a first-line treatment for biopolar disorder. |
| T121 |
766-844 |
Sentence |
denotes |
Yet the exact molecular target and mechanism of action remain unknown [36,37]. |
| T122 |
845-981 |
Sentence |
denotes |
Many diseases particularly those affect the nervous system like Alzheimer, Parkinson’s, and depression lack accurate biomarkers [38,39]. |
| T123 |
982-1163 |
Sentence |
denotes |
While progress is being made, the lack of reliable biomarkers remains another impediment for the accurate diagnosis, prognosis and effective drug development against these diseases. |
